The impact of smoking on nivolumab outcomes in renal cell carcinoma: Real-world data from the Turkish Oncology Group Kidney Cancer Consortium

Sertesen Camoz, Elif; BÖLEK, HATİCE; Kuzu, Omer; Sim, Saadet; Karakaş, Hilal; Sekmek, Serhat; Guliyev, Murad; Akkus, Aysun; Isik, Selver; Tural, DENİZ; Arslan, Cagatay; Goksu, SEMA; Sever, Ozlem; Karadurmuş, Nuri; Karacin, Cengiz; Ozguroglu, Mustafa; Sendur, Mehmet; Yekedüz, Emre; Ürün, Yüksel

doi:10.1093/oncolo/oyaf186

The impact of smoking on nivolumab outcomes in renal cell carcinoma: Real-world data from the Turkish Oncology Group Kidney Cancer Consortium

Atıf İçin Kopyala

Sertesen Camoz E., BÖLEK H., Kuzu O. F., Sim S., Karakaş H., Sekmek S., ...Daha Fazla

Oncologist, cilt.30, sa.7, 2025 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 30 Sayı: 7
Basım Tarihi: 2025
Doi Numarası: 10.1093/oncolo/oyaf186
Dergi Adı: Oncologist
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CINAHL, MEDLINE, Directory of Open Access Journals
Anahtar Kelimeler: metastatic, nivolumab, renal cell carcinoma, smoking
Akdeniz Üniversitesi Adresli: Evet

Özet

Background The study aims to evaluate the effect of smoking status on treatment results in patients with metastatic renal cell carcinoma (RCC) treated with nivolumab in the second and following lines of therapy. Materials and Methods The Turkish Oncology Group Kidney Cancer Consortium (TKCC) database was used to extract retrospective data from patients with metastatic RCC treated with nivolumab in the second line and beyond. Patients were evaluated according to their smoking status. Results A total of 247 patients were evaluated. The majority of the current smokers were male (93.8%, P = .002). Nivolumab is mainly used in the second-line therapy (84.2%). Median time to treatment failure (TTF) and median overall survival were shorter in patients with currently smoking (10.81 vs. 4.11 months, P < .001 and 32.33 vs. 16.76 months, P < .049, respectively). Multivariate analysis showed that current smoking status was an independent adverse factor on median TTF (HR 2.06 95% confidence interval (CI) = 1.20-3.54, P = .009) and median OS (, HR 2.06, 95% CI = 1.25-3.38, P = .004) in metastatic RCC patients treated with nivolumab in the second line and beyond. Conclusions Current smoking status is an independent adverse prognostic factor for both TTF and OS in patients with metastatic RCC treated with nivolumab in the second line and beyond.